by Peter Ciszewski | Dec 11, 2018
William T. Andrews, MD, FACP, Chief Medical Officer of Acer Therapeutics discusses his company’s focus on Vascular Ehlers-Danlos Syndrome (vEDS). Vascular Ehlers-Danlos syndrome (previously known as EDS Type IV or EDS IV) is an inherited connective tissue...
by Peter Ciszewski | Dec 10, 2018
Michael Jordan, MD, a physician-scientist in the division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center HLH Center of Excellence, discusses primary hemophagocytic lymphohistiocytosis (HLH) and the...
by Peter Ciszewski | Dec 10, 2018
This year’s American Society of Hematology (ASH) 2018 Annual Meeting was held on December 1-4 in San Diego, California. Physicians, researchers, and health care professionals learned about the latest advances in the treatment of blood cancers and blood...
by Peter Ciszewski | Dec 5, 2018
According to investigators from the CheckMate 436 trial, Nivolumab plus brentuximab vedotin may be a new treatment option for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). Interim results from this phase 1/2 trial revealed an...
by Peter Ciszewski | Dec 3, 2018
A Phase 3 clinical trial evaluating luspatercept in adults with beta-thalassemia-associated anemia met the primary endpoint. The results were presented at the American Society of Hematology (ASH) in San Diego. The phase 3 trial was a randomized, double-blind,...
